Capture.JPG (61.3 kB)

Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use

Download (61.3 kB)
online resource
posted on 08.03.2020 by Emma Deeks

Compliance with ethical standards

Funding: The preparation of this review was not supported by any external funding.

Conflicts of interest: Emma Deeks is an employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no conflicts of interest.

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit original author(s) and the source, provide a link to the Creative Commons licence and indicate if changes were made


Additional information about this Adis Drug Review can be found here


Abstract

Subcutaneous insulin glargine/lixisenatide [Suliqua® 100/33 and 100/50 (EU); Soliqua® 100/33 (USA)] is a titratable, fixed-ratio combination of a long-acting basal insulin analogue + a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved to treat inadequately controlled type 2 diabetes (T2D) in adults. Once-daily insulin glargine/lixisenatide provided glycaemic control better than that of insulin glargine or lixisenatide in insulin-naive patients (when added to metformin) and better than that of insulin glargine in insulin-experienced patients (when used ± metformin) in phase 3 trials in adults with inadequately controlled T2D. It also had a beneficial effect on bodyweight and did not increase the frequency of hypoglycaemia versus insulin glargine. Insulin glargine/lixisenatide is generally well tolerated and offers the convenience of once-daily administration of two subcutaneous antihyperglycaemic agents. It is, therefore, a valuable option for improving glycaemic control in adults with T2D when this has not been provided by metformin alone or metformin + another oral antihyperglycaemic agent or + basal insulin.


© Springer Nature 2019; corrected publication 2019





History

Exports

Read the peer-reviewed publication

Logo branding

Exports